Prospective evaluation of free radicals and antioxidant activity following 6-month risedronate treatment in patients with postmenopausal osteoporosis

Simple item page
dc.contributor.authorZinnuroglu M.
dc.contributor.authorDincel A.S.
dc.contributor.authorKosova F.
dc.contributor.authorSepici V.
dc.contributor.authorKaratas G.K.
dc.date.accessioned2024-07-22T08:19:35Z
dc.date.available2024-07-22T08:19:35Z
dc.date.issued2012
dc.description.abstractIn addition to the well-described implications of estrogen deficiency in postmenopausal osteoporosis (PMO), free radicals are also effective on bone metabolism. The antioxidant vitamins C and E play an important role in the production of collagen, mesenchymal cell differentiation into osteoblasts, and bone mineralization. Therefore, the incidence of osteoporosis and the risk of fractures were decreased with vitamin C and E. It was proposed that free oxygen radicals are responsible for biological aging, atherosclerosis, carcinogenesis, and osteoclastic activity via their negative effects on the cell and DNA. In this study, we aimed to investigate and compare the levels of free radicals and serum antioxidant activity in patients with PMO and healthy subjects before and after six-month treatment with risedronate, which is an inhibitor of bone resorption. Twenty-three postmenopausal patients aged between 52-83 (mean [± standard deviation] 67.6 ± 8.17) with T scores below -2.5 in femur neck or L1-L4, and 23 postmenopausal healthy subjects were enrolled into the study. Patients who had received any medications within the last 6 months that could alter bone metabolism were excluded. Serum malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione peroxidase (GPx) levels were analyzed in both groups. The patients with PMO were commenced on 5 mg of risedronate, 1,200 mg of calcium, and 800 IU of vitamin D daily. The patients were reevaluated at the end of the sixth month. MDA and SOD levels were similar in patients with PMO when compared to the healthy group before the treatment, while the GPx levels were lower in patients with PMO (P = 0.014). GPx (P = 0.028) and MDA (P = 0.04) levels were increased in patients with PMO after the treatment. In contrast, SOD levels were decreased when compared to the initial levels (P = 0.006). There may be an insufficiency in different steps of the enzymatic antioxidant systems in patients with PMO without treatment. We observed an increment in lipid peroxidation levels and GPx levels with risedronate. We think that the decrement in SOD levels may be related with the utilized antioxidants due to the increased free radicals and the compensatory increment in the other steps of the antioxidant system. © Springer-Verlag 2011.
dc.identifier.DOI-ID10.1007/s00296-010-1708-7
dc.identifier.issn1437160X
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/17751
dc.language.isoEnglish
dc.subjectAged
dc.subjectAntioxidants
dc.subjectBone Density
dc.subjectBone Density Conservation Agents
dc.subjectEtidronic Acid
dc.subjectFemale
dc.subjectFree Radicals
dc.subjectHumans
dc.subjectMiddle Aged
dc.subjectOsteoporosis, Postmenopausal
dc.subjectOxidative Stress
dc.subjectalpha tocopherol
dc.subjectascorbic acid
dc.subjectcalcium
dc.subjectfree radical
dc.subjectglutathione peroxidase
dc.subjectmalonaldehyde
dc.subjectoxygen radical
dc.subjectrisedronic acid
dc.subjectsuperoxide dismutase
dc.subjectvitamin D
dc.subjectadult
dc.subjectaged
dc.subjectantioxidant activity
dc.subjectarticle
dc.subjectbone atrophy
dc.subjectbone density
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectdual energy X ray absorptiometry
dc.subjectfemale
dc.subjectfollow up
dc.subjectfragility fracture
dc.subjecthuman
dc.subjectlipid peroxidation
dc.subjectoutcome assessment
dc.subjectpostmenopause osteoporosis
dc.subjectpriority journal
dc.subjectprospective study
dc.subjectrisk
dc.subjectscoring system
dc.subjecttreatment duration
dc.titleProspective evaluation of free radicals and antioxidant activity following 6-month risedronate treatment in patients with postmenopausal osteoporosis
dc.typeArticle

Files

Collections

Scopus Koleksiyonu